US Stock Market News | Latigo Biotherapeutics (LTGO.US) debuts on the US stock market, shares rise over 14% after opening
As of press time, the stock is up more than 14%, trading at $20.53.
According to Zhitong Finance APP, on Friday, non-opioid pain medication developer Latigo Biotherapeutics (LTGO.US) debuted on the US stock market, and as of press time, the stock was up more than 14%, trading at $20.53. Latigo is dedicated to developing non-opioid painkillers targeting the Nav1.8 sodium channel. Its core candidate drug, LTG-001, is an oral Nav1.8 inhibitor mainly used for the treatment of moderate to severe acute pain, including postoperative pain. This medication aims to provide pain relief comparable to opioids while avoiding the risk of addiction. Nav1.8 is mainly expressed in peripheral pain-sensing neurons, and its inhibitors do not act on the central nervous system, thus do not cause addiction.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "new Bond King" Gundlach warns: The next recession may trigger a US debt crisis, and US Treasury bonds will no longer be a safe haven.
The "new bond king" Jeffrey Gundlach has warned that the next round of economic downturn in the United States could trigger a debt crisis, pushing long-term U.S. Treasury yields sharply higher. This would break the decades-old conventional belief that bonds are always a safe haven during economic turbulence.
Nvidia (NVDA.US) further strengthens AI infrastructure by investing $2 billion in Brookfield (BAM.US) Global AI Fund, which aims to raise $10 billion.
Nvidia has invested $2 billion in the Global Artificial Intelligence Infrastructure Fund under Brookfield Asset Management.
LCNB Chief Wealth Officer Michael Miller to Retire
Loop Industries to Evaluate Alternatives, India Joint Venture Financing
Crypto prices
More
